Earlier we published information that Medrxiv, an Internet site distributing complete but unpublished manuscripts in the areas of medicine, clinical research, and related health sciences, published a meta-analysis of the randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death. It has not been certified by peer review and reported new medical research that had yet to be evaluated and should not guide clinical practice.

Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection

Medrxiv, an Internet site distributing complete but unpublished manuscripts in the areas of medicine and clinical research, published a meta-analysis of the randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death.

New York, NY. October 27, 2020 – Dr. Vladimir Zelenko and team announced today that a retrospective study analyzing his patient data was accepted for publication after a rigorous peer review process and was accepted for publication in the International Journal of Antimicrobial Agents (2020), doi: https://doi.org/10.1016/j.ijantimicag.2020.106214

The study finds that early intervention and treatment of high-risk patients with COVID-19 resulted in significantly fewer hospitalizations and deaths. The treatment consisting of zinc, low-dose hydroxychloroquine and azithromycin, is also referred to as “The Zelenko Protocol.”

This retrospective analysis is the product of the unique collaboration of three doctors with a rare synergy of industry, academia and clinical medicine. Dr. Roland Derwand is a German physician and life science industry expert. Professor Martin Scholz is an independent consultant and adjunct professor for experimental medicine at Heinrich Heine University, Düsseldorf, Germany. Drs. Derwand and Scholz were the first to draw attention to “The Zelenko Protocol” in their published hypothesis paper about the importance of combining zinc with hydroxychloroquine as a method for treating COVID-19.

The article can be found here.

It means that the paper can now be used in clinical practice and is to appear in the International Journal of Antimicrobial Agents.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The objective of the paper is to describe outcomes of patients with coronavirus disease 2019 (COVID- 19) in the outpatient setting after early treatment with zinc, low dose hydroxychloroquine, and azithromycin (triple therapy) dependent on risk stratification.

There are several reasons why it can save the lives of millions of people suffering from COVID-19:

  • First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.
  • Hydroxychloroquine at low dose in combination with zinc and azithromycin proved to be an effective therapeutic approach against COVID-19.
  • Significantly reduced hospitalization rates in the treatment group.
  • Reduced mortality rates in the treatment group.


Over the past months, Dr.Vladimir Zelenko has become known for claiming to have developed a drug regimen for treating coronavirus.

The Zelenko Protocol has shown an 84% reduction in hospitalizations in COVID-19 cases and a 0.71% death rate in high-risk patients (expected death rate was >5%). HCQ and Zinc may have a prophylactic and/or treatment role in the influenza virus.

It has been known for a long time that a treatment protocol exists that can reduce the mortality rate and help people get better sooner. The Internet Protocol team shared Dr. Zelenko’s treatment protocol multiple times, translated into many languages, emphasizing how important it is to start early coronavirus treatment.

Dr. Zelenko’s position and his treatment plan have been the subject of criticism. But many people supported the doctor’s position. For instance, an infectious disease doctor David Boulware and doctors from Harvard and Yale Medical Schools.

The Use of Zinc, Hydroxychloroquine, and Azithromycin are Associated with Less Death in COVID-19 Patients, a New Study Finds

The study reports a very low fatality rate of 0.71% in treated patients with confirmed positive cases of COVID-19.

Dr. Zelenko has even contacted US President Donald Trump and shared his COVID-19 treatment protocol with him.

The doctor is still appealing to the medical communities and patients, hoping that they will try and use the protocols he developed as he clearly shows how many lives can be saved in such difficult times if we all take action.

Leave a Reply

Your email address will not be published. Required fields are marked *